Liselotte Jansson, Phd

Biography

Liselotte Jansson is the Chief Research Officer of Apitope. Dr Jansson joined Apitope from AstraZeneca where she was Associate Director in the Dept. of Neuroscience, iMed Neuroscience area in Södertälje, Sweden. In this role, Dr Jansson headed the Good Laboratory Practices Animal Facility and her section delivered the in vivo models profiling of potential candidate drugs in the areas of pain and neurodegenerative diseases. Dr Jansson was also a member of new target generation team focusing on the neuroimmunological mechanisms in Alzheimer’s disease. Dr Jansson`s immunology career began with Professor Hans Wigzell, Dept. at Uppsala University and then the experimental rheumatology group led by Professor Lars Klareskog, characterizing collagen induced arthritis models. Her PhD thesis is focused on the immune modulatory role of sex hormones in experimental models of rheumatoid arthritis (CIA) and multiple sclerosis (EAE). In 1994, Dr Jansson moved to the Medical Inflammation Research section at Lund University, headed by Professor Rikard Holmdahl as Assistant Professor with focus on the immunological mechanisms and finding genes involved in peptide induced EAE. After five years at Lund University she was recruited into the Department for Immune Pharmacology at AstraZeneca in Lund as Associate Director and expert in in vivo experimental arthritis models, leading a group of scientists to find new therapies for rheumatoid arthritis. She also worked in gastrointestinal research as Disease Area Scientific Leader for Inflammatory Bowel Disease (IBD) with the remit to build a portfolio consisting of both small molecules and biopharmaceuticals. During her time at Astra Zeneca in Sweden and the UK, she took three candidates from research into clinical development. Dr Jansson has more than 40 scientific peer reviewed publications and patents.

Research Interest

Inflammatory Bowel Disease (IBD).